Data as of Mar 07
| -0.0001 / -0.00%|
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE: RDHL) is an emerging Israeli biopharmaceutical company focused primarily on the acquisition and development of late clinical-stage proprietary formulations and combinations of existing drugs. The Company's lead programs currently undergoing Phase III clinical trials in the U.S. are RHB-104 for Crohn's disease and RHB-105 for H. pylori infection. RedHill's most advanced programs are RHB-103, an oral thin film rizatriptan for the treatment of acute migraines, and RHB-102, a once-daily oral ondansetron, an oncology support anti-emetic drug. The Company's advanced pipeline also includes RHB-106, an encapsulated formulation for bowel preparation, and RHB-101, a once-daily formulation of carvedilol for the treatment of congestive heart failure and hypertension. RedHill Biopharma was founded on August 3, 2009 and is headquartered in Tel Aviv, Israel.
|Dror Ben-Asher||Chairman & Chief Executive Officer|
|Ori Shilo||Director, Deputy CEO-Finance & Operations|
|Ira N. Kalfus||Medical Director|
|Reza Fathi||Senior Vice President-Research & Development|
|Thomas A. Lang||Vice President-Regulatory & Clinical Affairs|